Prolonged profound abciximab associated immune thrombocytopenia complicated by transient multispecific platelet antibodies.
Patients receiving abciximab occasionally develop transient severe thrombocytopenia within a few hours of receiving the drug. Thrombocytopenia has been reported to resolve within 10 days of abciximab administration, but in this case profound thrombocytopenia lasted 21 days before a slow spontaneous recovery. Management was complicated by the presence of HLA antibodies and the transient production of antibodies directed at major platelet glycoproteins IIb/IIIa, Ib/IX, and Ia/IIa. The patient remained refractory to platelet transfusion and two courses of intravenous gammaglobulin for the duration of her admission.
Lown
J A G
JA
Department of Haematology, Royal Perth Hospital, Perth, Western Australia, Australia. john.lown@health.wa.gov.au
Hughes
A S
AS
Cannell
P
P
D000077284:Abciximab; D000328:Adult; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D001323:Autoantibodies / Q000032:analysis*; D001327:Autoimmune Diseases / Q000139:chemically induced* / Q000276:immunology; D001792:Blood Platelets / Q000276:immunology*; D023921:Coronary Stenosis / Q000601:surgery; D005260:Female; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000009:adverse effects*; D010975:Platelet Aggregation Inhibitors / Q000009:adverse effects*; D015607:Stents; D013921:Thrombocytopenia / Q000139:chemically induced* / Q000276:immunology
D000911:Antibodies, Monoclonal; D001323:Autoantibodies; D007140:Immunoglobulin Fab Fragments; D010975:Platelet Aggregation Inhibitors; D000077284:Abciximab